CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03564340
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:54.046075+00:00
Published At: 2025-12-03T00:00:00+00:00
Record Updated At: 2025-12-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Ovarian Cancer", "Recurrent Fallopian Tube Cancer", "Recurrent Primary Peritoneal Cancer", "Recurrent Endometrial Cancer", "Endometrial Cancer", "Low-grade Serous Ovarian Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-03"
protocolSection.identificationModule.nctId: "NCT03564340"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16\u00d7CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.